Akari Therapeutics PLC Form 4 insider transactions

Raymond Prudo-Chlebosz, a director of Akari Therapeutics Plc, acquired shares and warrants in a private placement on March 6, 2025.

Director Samir Rashmikant Patel acquires shares and warrants in Akari Therapeutics via a private placement.

Director James R. Neal acquired 4,464 American Depositary Shares (ADS) and accompanying warrants in Akari Therapeutics' private placement on March 6, 2025.

Robert Bazemore, a director of Akari Therapeutics Plc, acquired American Depositary Shares (ADS) and warrants in a private placement on March 6, 2025.

Director Abizer Gaslightwala reports acquiring and disposing of Akari Therapeutics shares and warrants in a private placement.

An Akari Therapeutics director, Abizer Gaslightwala, amended a previous SEC filing to correct the number of American Depository Shares (ADS) purchased and the total amount beneficially owned.

Director Abizer Gaslightwala of Akari Therapeutics Plc acquired 11,439 American Depository Shares at $1.22 each on January 10, 2025.

Akari Therapeutics CFO, Torsten Hombeck, engaged in a transaction involving the acquisition and disposal of 200 American Depository Shares (ADS) on January 10, 2025.

Director James R. Neal of Akari Therapeutics Plc acquired 8,000,000 ordinary shares at a price of $0.00065 per share on January 9, 2025.

Director Abizer Gaslightwala reports acquiring 1,720,000 ordinary shares of Akari Therapeutics Plc on January 3, 2025.

Director Samir Rashmikant Patel reports acquisition of Akari Therapeutics shares and options at a price of $0.0006 per share on January 3, 2025.

Director Samir Rashmikant Patel acquired 3.6 million ordinary shares of Akari Therapeutics at $0.0005 per share through PranaBio Investments LLC.

Director Abizer Gaslightwala reports acquiring 40,000,000 and disposing of 70,000,000 ordinary shares of Akari Therapeutics Plc on December 27, 2024.

Director Abizer Gaslightwala acquired 30 million shares of Akari Therapeutics at $0.0005 per share on December 26, 2024.

Director Samir Rashmikant Patel acquired 7,500,000 ordinary shares of Akari Therapeutics at $0.0005 per share on December 24, 2024.

Director James R. Neal of Akari Therapeutics Plc reports the acquisition of 2,000,000 ordinary shares at a price of $0.0005 per share on December 23, 2024.

Samir Rashmikant Patel, a director of Akari Therapeutics Plc, acquired 1,400,000 ordinary shares at $0.0005 per share on December 23, 2024.

Director Samir Rashmikant Patel reports the acquisition of 1,400,000 ordinary shares of Akari Therapeutics Plc at a price of $0.0005 per share on December 20, 2024.

Akari Therapeutics director, Samir Rashmikant Patel, acquired a substantial amount of shares and warrants through a private placement, significantly increasing his beneficial ownership.

Akari Therapeutics director Raymond Prudo-Chlebosz acquired 419,286,000 ordinary shares and warrants in a private placement on December 2, 2024.

Akari Therapeutics director, Samir Rashmikant Patel, reports acquiring a substantial number of ordinary shares following the merger with Peak Bio.

Director Samir Rashmikant Patel acquired 79,684,000 stock options in Akari Therapeutics Plc on October 31, 2024.

Akari Therapeutics announces the SEC's declaration of effectiveness for its Form S-4 related to the Peak Bio merger and schedules a General Meeting for shareholder approval on November 7, 2024.

Director Samir Rashmikant Patel acquires stock options in Akari Therapeutics Plc.

Director Robert B. Bazemore of Akari Therapeutics Plc was granted 5,000,000 non-qualified stock options under the company's 2023 Equity Incentive Plan.

Director Michael Grissinger of Akari Therapeutics Plc was granted 5,000,000 stock options under the company's 2023 Equity Incentive Plan.

Director Samir Rashmikant Patel acquired 91,396,000 ordinary shares in Akari Therapeutics through restricted stock units and granted a power of attorney.

Director Mohamed Wa'el Hashad of Akari Therapeutics Plc was granted 5,000,000 non-qualified stock options under the company's 2023 Equity Incentive Plan.

Donald A. Williams, a director at Akari Therapeutics Plc, was granted 5,000,000 stock options under the company's 2023 Equity Incentive Plan.

Raymond Prudo-Chlebosz, a director at Akari Therapeutics Plc, was granted 10,000,000 stock options under the company's 2023 Equity Incentive Plan.